150 related articles for article (PubMed ID: 36305339)
1. D-dimer levels decline after immunosuppressive treatment rather than anticoagulant treatment in severe autoimmune chronic spontaneous urticaria.
Baskurt D; Sarac E; Asero R; Kocatürk E
Eur Ann Allergy Clin Immunol; 2024 Jan; 56(1):42-44. PubMed ID: 36305339
[TBL] [Abstract][Full Text] [Related]
2. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
Asero R; Marzano AV; Ferrucci S; Cugno M
Int Arch Allergy Immunol; 2017; 172(1):40-44. PubMed ID: 28219067
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
4. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
Asero R
Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
[TBL] [Abstract][Full Text] [Related]
5. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
[TBL] [Abstract][Full Text] [Related]
6. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
Gimenez-Arnau AM; Salman A; Podder I
Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
[TBL] [Abstract][Full Text] [Related]
8. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2022 Jan; 54(1):30-33. PubMed ID: 33555151
[No Abstract] [Full Text] [Related]
9. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
10. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU.
Asero R; Marzano AV; Ferrucci S; Cugno M
J Allergy Clin Immunol Pract; 2017; 5(6):1740-1742. PubMed ID: 28866106
[No Abstract] [Full Text] [Related]
11. Activation of coagulation in chronic urticaria in relation to disease severity and activity.
Farres MN; Refaat M; Melek NA; Ahmed EE; Shamseldine MG; Arafa NA
Allergol Immunopathol (Madr); 2015; 43(2):162-7. PubMed ID: 25088671
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
13. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
15. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
[TBL] [Abstract][Full Text] [Related]
17. Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab.
Di Pino M; Ruberto MF; Costanzo G; Firinu D; Piras MS; Mura MN; Del Giacco S; Coghe F; Marongiu F; Barcellona D
Clin Exp Med; 2023 Jun; 23(2):495-502. PubMed ID: 35614365
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
Mehta H; Bishnoi A; Parsad D; Kumaran MS
Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
[TBL] [Abstract][Full Text] [Related]
19. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
Maurer M; Zuberbier T; Metz M
Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]